General MedicationsORALGeneric
UCEPHAN
SODIUM BENZOATE; SODIUM PHENYLACETATE
Standard Dose
100MG/ML;100MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview UCEPHAN is listed in Drugs@FDA under application 019530 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient SODIUM BENZOATE; SODIUM PHENYLACETATE Form and strength SOLUTION;ORAL - 100MG/ML;100MG/ML Sponsor B BRAUN Submission history Latest submission status date: 1987-12-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview UCEPHAN is listed in Drugs@FDA under application 019530 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient SODIUM BENZOATE; SODIUM PHENYLACETATE Form and strength SOLUTION;ORAL - 100MG/ML;100MG/ML Sponsor B BRAUN Submission history Latest submission status date: 1987-12-23 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.